CR11355A - Derivados de quinazolinona 6-, 7-, u 8-sustituidos y composiciones que los comprenden - Google Patents

Derivados de quinazolinona 6-, 7-, u 8-sustituidos y composiciones que los comprenden

Info

Publication number
CR11355A
CR11355A CR11355A CR11355A CR11355A CR 11355 A CR11355 A CR 11355A CR 11355 A CR11355 A CR 11355A CR 11355 A CR11355 A CR 11355A CR 11355 A CR11355 A CR 11355A
Authority
CR
Costa Rica
Prior art keywords
compositions
quinazolinona
substitutes
derivatives
understand
Prior art date
Application number
CR11355A
Other languages
English (en)
Inventor
George W Muller
Hong Wa Man
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CR11355A publication Critical patent/CR11355A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a una invencion farmaceutica en donde se proveen compuestos de quinazolinona. Se describen composiciones farmaceuticas de estos compuestos.
CR11355A 2007-09-26 2010-04-07 Derivados de quinazolinona 6-, 7-, u 8-sustituidos y composiciones que los comprenden CR11355A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99567607P 2007-09-26 2007-09-26

Publications (1)

Publication Number Publication Date
CR11355A true CR11355A (es) 2010-06-21

Family

ID=40225265

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11355A CR11355A (es) 2007-09-26 2010-04-07 Derivados de quinazolinona 6-, 7-, u 8-sustituidos y composiciones que los comprenden

Country Status (22)

Country Link
US (5) US8492395B2 (es)
EP (1) EP2200999B1 (es)
JP (1) JP5637852B2 (es)
KR (1) KR101593242B1 (es)
CN (2) CN101952272B (es)
AU (1) AU2008305581C1 (es)
BR (1) BRPI0817525A2 (es)
CA (1) CA2704710C (es)
CO (1) CO6270228A2 (es)
CR (1) CR11355A (es)
ES (1) ES2523925T3 (es)
HK (1) HK1139934A1 (es)
IL (2) IL204763A (es)
MX (1) MX347987B (es)
MY (1) MY157495A (es)
NI (1) NI201000041A (es)
NZ (1) NZ584425A (es)
RU (1) RU2476432C2 (es)
SG (2) SG10201503486XA (es)
UA (1) UA102078C2 (es)
WO (1) WO2009042177A1 (es)
ZA (1) ZA201002303B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2420498T3 (pl) 2006-09-26 2017-10-31 Celgene Corp 5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe
US8354417B2 (en) * 2007-09-26 2013-01-15 Celgene Corporation Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
KR101651312B1 (ko) * 2009-08-31 2016-08-25 머크 샤프 앤드 돔 코포레이션 피라닐 아릴 메틸 벤조퀴나졸리논 ｍ1 수용체 양성 알로스테릭 조절제
WO2011049731A1 (en) 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
HUE027481T2 (en) * 2011-03-11 2016-09-28 Celgene Corp Methods of treating cancer with 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2,6-dione
PE20140983A1 (es) 2011-03-11 2014-08-25 Celgene Corp Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014152833A1 (en) * 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
TW201534305A (zh) 2013-05-03 2015-09-16 Celgene Corp 使用組合療法治療癌症之方法
RS64038B1 (sr) 2014-08-22 2023-04-28 Celgene Corp Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
KR20180023968A (ko) 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CN108473461B (zh) 2016-01-14 2021-06-15 康朴生物医药技术（上海）有限公司 喹唑啉酮衍生物、其制备方法、药物组合物及应用
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
KR102014478B1 (ko) * 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2018208123A1 (ko) * 2017-05-12 2018-11-15 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
CN111885914B (zh) * 2017-10-27 2022-05-13 投资健康有限责任公司 使用芴衍生物制造扩增的造血干细胞的组合物和方法
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
SG11202109024YA (en) 2019-04-12 2021-09-29 C4 Therapeutics Inc Tricyclic degraders of ikaros and aiolos
US11807620B2 (en) 2020-02-21 2023-11-07 Plexium, Inc. Quinazolinone compounds and related compounds
US20230303539A1 (en) * 2020-08-14 2023-09-28 Shanghaitech University Immunoregulatory compound and antitumor application thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
ES2198546T3 (es) * 1996-05-15 2004-02-01 Pfizer Inc. 4(3h)-quinazolinonas 2,3,6 trisustituidas.
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE69717831T3 (de) 1996-07-24 2018-08-30 Celgene Corp. Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CN100390163C (zh) * 1998-03-16 2008-05-28 赛尔金有限公司 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
AU2002343220A1 (en) 2001-11-09 2003-05-19 Matsushita Electric Industrial Co., Ltd. Moving picture coding method and apparatus
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
JP2006501201A (ja) * 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
NZ548049A (en) 2003-12-02 2009-01-31 Celgene Corp Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
NZ550026A (en) 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
NZ551004A (en) * 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
CA2563810A1 (en) 2004-04-23 2005-11-10 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
EP1761506A1 (en) * 2004-06-15 2007-03-14 AstraZeneca AB Substituted quinazolones as anti-cancer agents
AU2005304420A1 (en) 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
US20060122228A1 (en) 2004-11-23 2006-06-08 Zeldis Jerome B Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
CA2588990A1 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
KR20080042158A (ko) 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
ES2359162T3 (es) 2005-09-01 2011-05-19 Celgene Corporation Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas.
PL2420498T3 (pl) * 2006-09-26 2017-10-31 Celgene Corp 5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe

Also Published As

Publication number Publication date
CN101952272B (zh) 2014-08-27
RU2010116273A (ru) 2011-11-10
SG176442A1 (en) 2011-12-29
EP2200999A1 (en) 2010-06-30
EP2200999B1 (en) 2014-08-13
KR20100080540A (ko) 2010-07-08
ZA201002303B (en) 2011-06-29
SG10201503486XA (en) 2015-06-29
MY157495A (en) 2016-06-15
ES2523925T3 (es) 2014-12-02
MX347987B (es) 2017-05-22
IL204763A (en) 2013-07-31
UA102078C2 (ru) 2013-06-10
RU2476432C2 (ru) 2013-02-27
US20090093504A1 (en) 2009-04-09
US20130289274A1 (en) 2013-10-31
IL204763A0 (en) 2010-11-30
AU2008305581C1 (en) 2014-12-11
NZ584425A (en) 2012-03-30
KR101593242B1 (ko) 2016-02-11
US20180118713A1 (en) 2018-05-03
CO6270228A2 (es) 2011-04-20
IL226870A (en) 2014-11-30
US9586929B2 (en) 2017-03-07
US20150291555A1 (en) 2015-10-15
JP5637852B2 (ja) 2014-12-10
CA2704710C (en) 2016-02-02
US9096573B2 (en) 2015-08-04
BRPI0817525A2 (pt) 2014-11-18
MX2010003355A (es) 2010-04-14
CA2704710A1 (en) 2009-04-02
HK1139934A1 (en) 2010-09-30
AU2008305581B2 (en) 2013-12-05
CN104211684A (zh) 2014-12-17
JP2010540525A (ja) 2010-12-24
US9834538B2 (en) 2017-12-05
US8492395B2 (en) 2013-07-23
WO2009042177A1 (en) 2009-04-02
IL226870A0 (en) 2013-07-31
US20170129873A1 (en) 2017-05-11
AU2008305581A1 (en) 2009-04-02
NI201000041A (es) 2010-09-09
CN101952272A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
CR11355A (es) Derivados de quinazolinona 6-, 7-, u 8-sustituidos y composiciones que los comprenden
HN2007000437A (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
SV2011003884A (es) Arilpirrolidinas pesticidas
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
SMT201500316B (it) Derivati di benzotiazolo come agenti anticancro
HN2011003371A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CR11653A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR9442A (es) Nuevos compuestos farmaceuticos
HN2012000437A (es) Nuevos agentes anticancer y la preparacion de dichos agentes
NI200900031A (es) Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos.
HN2011003195A (es) Modulares de gpr 119
CR11819A (es) Compuestos de isoindolina 5-sustituidos
UY30840A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos
CR11481A (es) Antagonista de la ruta de hedgehog y aplicaciones terapeuticas de los mismos
HN2011003002A (es) Compuesto de haloalquilo heteroarilo benzamida
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
CR20110680A (es) Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2011002258A1 (es) Compuestos derivados heterociclicos fusionados; composicion farmaceutica que los comprende; y uso de los compuestos para tratar vih.